Our Pricing

Mounjaro And UTI: Understanding Safety & Side Effects

Published on: June 03, 2026

Concerns about mounjaro and uti risk uk are common among patients considering tirzepatide treatment for weight loss. At Cured Pharmacy, our UK-registered clinical team regularly addresses questions about urinary tract infections and Mounjaro safety. Whilst UTIs are not listed as a primary side effect in clinical trials, understanding the relationship between GLP-1 medications and urinary health helps you make informed decisions about your treatment.

Does Mounjaro Directly Cause Urinary Tract Infections?

Urinary tract infections were not identified as a significant adverse event in the major SURPASS clinical trials evaluating tirzepatide safety across over 6,000 participants [1]. Unlike SGLT2 inhibitors (a different class of diabetes medication), Mounjaro does not increase glucose levels in urine, which is the primary mechanism by which some diabetes treatments elevate UTI risk.

However, the weight loss and metabolic changes induced by Mounjaro can indirectly affect urinary health. Patients losing significant body weight may experience changes in fluid balance, hydration patterns, and bathroom habits that could theoretically influence infection susceptibility [2]. These are manageable factors rather than direct medication effects.

Our superintendent pharmacist Tarun Kumar notes that in clinical practice, reported UTI concerns among Mounjaro patients typically relate to dehydration from gastrointestinal side effects rather than the medication's primary mechanism of action. Maintaining adequate hydration throughout treatment is essential for both efficacy and urinary tract health.

Understanding Mounjaro's Mechanism and Urinary System Impact

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA in the UK [1]. It works by mimicking two natural hormones that regulate appetite, blood sugar control, and gastric emptying. Importantly, tirzepatide does not alter kidney filtration of glucose or directly affect urinary tract physiology in the way that increases infection risk.

The medication's primary side effects centre on the gastrointestinal system, with nausea, diarrhoea, and reduced appetite being most common during dose escalation [3]. These effects can lead to decreased fluid intake or increased fluid loss, potentially creating conditions where urinary tract health requires extra attention.

Dehydration and Urinary Health During Treatment

Dehydration represents the most significant indirect link between Mounjaro treatment and potential urinary complications. When patients experience nausea or reduced thirst alongside appetite suppression, daily fluid intake may drop below optimal levels. Concentrated urine and infrequent urination can increase susceptibility to bacterial colonisation in the urinary tract.

Clinical guidance recommends maintaining at least 2 litres of fluid daily during Mounjaro treatment, adjusted for individual needs and activity levels. This supports both the medication's weight loss effects and urinary tract protection.

Mounjaro and UTI Risk UK: What Clinical Evidence Shows

Post-marketing surveillance data from the MHRA and real-world evidence studies have not identified UTIs as a pattern of concern specific to tirzepatide treatment [4]. This differs markedly from certain diabetes medications where urinary infections represent a well-documented class effect requiring specific patient counselling.

In the SURPASS-2 trial comparing tirzepatide directly with semaglutide, genitourinary adverse events occurred at similar low rates across both treatment groups, suggesting no elevated risk compared to other GLP-1 receptor agonists [1]. The safety profile remains consistent across different patient populations, including those with varying degrees of renal function.

Individual case reports of UTIs during Mounjaro treatment typically involve patients with pre-existing risk factors such as diabetes history, recurrent infection patterns, or inadequate hydration practices. These represent patient-specific vulnerabilities rather than medication-induced complications.

Preventing Urinary Tract Infections During Mounjaro Treatment

Proactive hydration strategies form the cornerstone of UTI prevention whilst taking Mounjaro. Set regular fluid intake reminders, particularly during the first 8-12 weeks when gastrointestinal side effects peak and appetite suppression is most pronounced. Water remains the optimal choice, though sugar-free squash and herbal teas contribute to daily fluid goals.

Maintain regular urination patterns even when appetite and thirst signals diminish. Holding urine for extended periods allows bacterial multiplication in the bladder. Aim to empty your bladder every 3-4 hours during waking hours, and always urinate before bed and upon waking.

Personal hygiene practices gain additional importance during weight loss treatment. Wipe front to back after toilet use, wear breathable cotton underwear, and avoid prolonged exposure to damp clothing after exercise. These evidence-based measures reduce bacterial transfer to the urinary tract opening.

When to Seek Medical Advice

Contact your prescriber or GP immediately if you develop classic UTI symptoms during Mounjaro treatment: burning sensation during urination, frequent urgent need to urinate with minimal output, cloudy or strong-smelling urine, lower abdominal pain, or visible blood in urine. Early antibiotic treatment prevents progression to kidney infection.

Fever above 38°C combined with urinary symptoms, back or flank pain, nausea, or vomiting may indicate pyelonephritis (kidney infection) requiring urgent medical assessment. Do not delay seeking care if symptoms escalate rapidly or you feel systemically unwell.

Comparing Mounjaro Safety with Alternative Weight Loss Treatments

When evaluating urinary tract safety across weight loss medications available through UK pharmacies, Mounjaro demonstrates a favourable profile. Alternative GLP-1 treatments including Wegovy (semaglutide) and Saxenda (liraglutide) share similar mechanisms and safety characteristics regarding urinary health, with no class-wide UTI concerns identified in regulatory reviews [2][3].

Orlistat-based treatments such as Xenical work through an entirely different mechanism, blocking fat absorption in the intestine rather than affecting hormonal appetite regulation. Whilst Orlistat does not influence urinary tract infection risk, its gastrointestinal side effects can indirectly affect hygiene practices that relate to UTI prevention.

Your UK prescriber will assess your complete medical history, including any recurrent UTI patterns, when determining the most appropriate weight loss treatment. Patients with frequent urinary infections are not automatically excluded from Mounjaro treatment but may receive enhanced counselling on hydration and monitoring strategies.

Starting Mounjaro Treatment Safely at Cured Pharmacy

All patients beginning Mounjaro at Cured Pharmacy complete a comprehensive online clinical assessment reviewed by UK-registered prescribers. This evaluation identifies pre-existing UTI risk factors, kidney function status, and diabetes history that may influence your treatment plan and monitoring requirements. The consultation takes under 3 minutes but ensures safe, personalised prescribing.

Mounjaro is available from £124.99 at Cured Pharmacy, with transparent upfront pricing shown before your consultation. Your prescribed dose depends on clinical assessment and follows MHRA-approved escalation schedules designed to minimise side effects whilst optimising weight loss outcomes. All medications dispensed are genuine UK-licensed products requiring prescription authorisation.

Our clinical team provides ongoing support throughout your treatment journey. If you develop any concerning symptoms including urinary changes, contact us through your patient portal or call our pharmacy team on (+44) 116 4646009. Adjustments to dosing, additional hydration guidance, or referral for further investigation can be arranged promptly to ensure your safety and treatment success.

What to Expect from Your Clinical Assessment

Your online consultation covers medical history, current medications, kidney function, and any history of urinary tract problems. Be prepared to disclose previous UTI frequency, any ongoing urological conditions, and your typical daily fluid intake. This information helps your prescriber identify whether additional monitoring or preventive strategies would benefit your specific situation.

Following prescription approval, you'll receive detailed patient information covering Mounjaro administration technique, expected side effects, and red-flag symptoms requiring medical attention. Urinary health guidance forms part of this comprehensive counselling, ensuring you understand both common experiences and genuine warning signs during treatment.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro (tirzepatide): Summary of Product Characteristics. MHRA. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. If you develop symptoms of a urinary tract infection or other concerning side effects during treatment, seek prompt medical attention from your GP or prescriber.